Cara Therapeutics | CARA - Net Income


Cara Therapeutics reported $-5.53M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
Assertio Holdings USD -2.92M 753K Sep/2024
Cara Therapeutics USD -5.53M 621K Sep/2025
Cassava Sciences USD -12.54M 1.73M Dec/2025
Chugai Pharma JPY 115.42B 12.99B Mar/2026
Cipla INR 5.55B 1.21B Mar/2026
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD 56.84M 63.82M Dec/2025
CSL USD 401M 96.5M Dec/2025
Grifols EUR 114.37M 34.03M Dec/2025
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
J&J USD 5.24B 119M Mar/2026
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Pacira USD 2.92M 1.28M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
RedHill Biopharma USD -1.54M 0 Jun/2024
Supernus Pharmaceuticals USD -2.29M 1.81M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024